JP2005516604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516604A5 JP2005516604A5 JP2003565304A JP2003565304A JP2005516604A5 JP 2005516604 A5 JP2005516604 A5 JP 2005516604A5 JP 2003565304 A JP2003565304 A JP 2003565304A JP 2003565304 A JP2003565304 A JP 2003565304A JP 2005516604 A5 JP2005516604 A5 JP 2005516604A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- sequence
- polypeptide
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims 55
- 229920001184 polypeptide Polymers 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 33
- 102000039446 nucleic acids Human genes 0.000 claims 25
- 108020004707 nucleic acids Proteins 0.000 claims 25
- 150000007523 nucleic acids Chemical class 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 23
- 125000003729 nucleotide group Chemical group 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 14
- 208000019838 Blood disease Diseases 0.000 claims 12
- 208000014951 hematologic disease Diseases 0.000 claims 12
- 208000018706 hematopoietic system disease Diseases 0.000 claims 12
- 102000003835 leukotriene receptors Human genes 0.000 claims 12
- 108090000146 leukotriene receptors Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 230000011132 hemopoiesis Effects 0.000 claims 6
- 210000000130 stem cell Anatomy 0.000 claims 6
- 208000031220 Hemophilia Diseases 0.000 claims 3
- 208000009292 Hemophilia A Diseases 0.000 claims 3
- 208000002903 Thalassemia Diseases 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35433302P | 2002-02-04 | 2002-02-04 | |
| US36025802P | 2002-02-28 | 2002-02-28 | |
| US36447602P | 2002-03-15 | 2002-03-15 | |
| US37562602P | 2002-04-26 | 2002-04-26 | |
| US38649402P | 2002-06-06 | 2002-06-06 | |
| US39096502P | 2002-06-24 | 2002-06-24 | |
| US39248002P | 2002-06-28 | 2002-06-28 | |
| US39412802P | 2002-07-03 | 2002-07-03 | |
| US39978302P | 2002-07-31 | 2002-07-31 | |
| US40322102P | 2002-08-13 | 2002-08-13 | |
| US40704502P | 2002-08-30 | 2002-08-30 | |
| US42904802P | 2002-11-25 | 2002-11-25 | |
| PCT/US2003/002484 WO2003065871A2 (en) | 2002-02-04 | 2003-01-28 | Methods and compositions for treating hematological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516604A JP2005516604A (ja) | 2005-06-09 |
| JP2005516604A5 true JP2005516604A5 (enExample) | 2006-03-09 |
Family
ID=27739578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565304A Pending JP2005516604A (ja) | 2002-02-04 | 2003-01-28 | １３１、１４８、１９９、１２３０３、１３９０６、１５５１３、１７８２２、３０２、５６７７、１９４、１４３９３、２８０５９、７３６６、１２２１２、１９８１、２６１、１２４１６、２７０、１４１０、１３７、１８７１、１３０５１、１８４７、１８４９、１５４０２、３４０、１０２１７、８３７、１７６１、８９９０または１３２４９分子を用いて血液障害を処置するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7250262B2 (enExample) |
| EP (1) | EP1471818A4 (enExample) |
| JP (1) | JP2005516604A (enExample) |
| AU (1) | AU2003214920A1 (enExample) |
| WO (1) | WO2003065871A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006010492A1 (en) * | 2004-07-28 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with tryptase 1 (tps1) |
| EP2275547B1 (en) | 2004-12-13 | 2014-03-05 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| US7785807B2 (en) * | 2004-12-13 | 2010-08-31 | Monell Chemical Senses Center | Voltage-gated, pH-sensitive anion channel and its novel splice variant involved in taste sensation |
| CA3012803C (en) | 2008-11-06 | 2023-08-08 | Indiana University Research & Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| EP3269802B1 (en) | 2011-09-30 | 2019-10-23 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| ES2992295T3 (es) | 2016-02-12 | 2024-12-11 | Bluebird Bio Inc | Composiciones potenciadoras de Vcn y métodos de uso de las mismas |
| US11326183B2 (en) | 2016-02-12 | 2022-05-10 | Bluebird Bio, Inc. | VCN enhancer compositions and methods of using the same |
| EP3507371B1 (en) * | 2016-08-31 | 2026-01-28 | Rutgers, The State University of New Jersey | Compositions for treating diseases and disorders of the nervous system |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880260A (en) | 1988-11-18 | 1999-03-09 | Oregon Health Sciences University | Dopamine receptors and genes |
| DE19922443A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen |
| CA2378249A1 (en) * | 1999-07-14 | 2001-01-25 | Mirella Ezban | Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis |
| JP2002000279A (ja) | 1999-10-08 | 2002-01-08 | Chugai Bunshi Igaku Kenkyusho:Kk | 初期造血に関わるｙｓ６８遺伝子 |
| EP1227148A4 (en) | 1999-10-08 | 2003-04-16 | Chugai Pharmaceutical Co Ltd | EARLY BLOODING GENE YS68 |
| DE10102977A1 (de) | 2001-01-23 | 2002-08-01 | Thomas Jentsch | Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose |
| US20030033625A1 (en) | 2001-03-29 | 2003-02-13 | Allen Keith D. | Transgenic mice containing CLCN4 chloride ion channel gene disruptions |
| AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
-
2003
- 2003-01-28 EP EP03710764A patent/EP1471818A4/en not_active Withdrawn
- 2003-01-28 JP JP2003565304A patent/JP2005516604A/ja active Pending
- 2003-01-28 US US10/352,684 patent/US7250262B2/en not_active Expired - Fee Related
- 2003-01-28 WO PCT/US2003/002484 patent/WO2003065871A2/en not_active Ceased
- 2003-01-28 AU AU2003214920A patent/AU2003214920A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522999A5 (enExample) | ||
| CA2413857A1 (en) | Pd-l2 molecules: pd-1 ligands and uses therefor | |
| JP2003501038A5 (enExample) | ||
| FR14C0061I2 (fr) | Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map) | |
| JP2007506426A5 (enExample) | ||
| JP2009502116A5 (enExample) | ||
| JP2006517788A5 (enExample) | ||
| JP2007516714A5 (ja) | 間葉系前駆細胞の骨芽細胞への分化を誘導する化合物の同定方法 | |
| AU726738B2 (en) | Diagnosis of epithelial cell abnormalities | |
| JP2005516604A5 (enExample) | ||
| JP2005516605A5 (enExample) | ||
| JP2005535289A5 (enExample) | ||
| JP2005507648A5 (enExample) | ||
| JP2005525112A5 (enExample) | ||
| JP2005512558A5 (enExample) | ||
| JP2006503575A5 (enExample) | ||
| Kiewitz et al. | Mapping of protein‐protein interactions between c‐myb and its coactivator CBP by a new phage display technique | |
| JP2002536989A5 (enExample) | ||
| JP2005508169A5 (enExample) | ||
| JP2005513054A5 (enExample) | ||
| JP2005508633A5 (enExample) | ||
| JP2005512528A5 (enExample) | ||
| JP2005504830A5 (enExample) | ||
| JP2005509174A5 (enExample) | ||
| JP2005507651A5 (enExample) |